The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress
- Resource Type
- Source
- Annals of Oncology. 29:v82
- Subject
0301 basic medicine Oncology medicine.medical_specialty business.industry Colorectal cancer Wild type Phases of clinical research Hematology medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Second line 030220 oncology & carcinogenesis Internal medicine medicine FOLFIRI business Aflibercept medicine.drug - Language
- ISSN
- 0923-7534